Daiichi-Sankyo's offer for 20% more in Ranbaxy delayed
This article was originally published in Scrip
Executive Summary
Daiichi-Sankyo's open offer to acquire an additional 20% stake from the shareholders of Ranbaxy Laboratorieshas yet to be approved by the Securities and Exchange Board of India (SEBI), forcing a revision in the "schedule of activities" pertaining to the offer. The offer was originally scheduled to open on August 8th and close on August 27th.